Ono Pharmaceutical Co Ltd 2016 Integrated Report
The report presents a strong FY2015 financial result, with consolidated revenue of ¥160,284 million and operating profit of ¥30,507 million. It describes continued expansion of OPDIVO and broader oncology capabilities as key business highlights. Environmental reporting records a 17.2% reduction in CO2 emissions from production and research sites compared with FY2005, alongside ongoing energy-saving initiatives. The report also reproduces a limited independent assurance report covering its Energy-derived CO2 Emissions.
Company: Ono Pharmaceutical Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2016
Type: Integrated Report
Pages: 124
Back to company
Ono Pharmaceutical Co Ltd
Corporate Report
The report presents a strong FY2015 financial result, with consolidated revenue of ¥160,284 million and operating profit of ¥30,507 million. It describes continued expansion of OPDIVO and broader oncology capabilities as key business highlights. Environmental reporting records a 17.2% reduction in CO2 emissions from production and research sites compared with FY2005, alongside ongoing energy-saving initiatives. The report also reproduces a limited independent assurance report covering its Energy-derived CO2 Emissions.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Apr 1, 2015 - Mar 31, 2016
Fiscal Year
2015
Published
Aug 1, 2016
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Employees